AstraZeneca's cediranib Ⅲ clinical study fails again
In the second pivotal clinical study suffered defeat after the results came out, the company decided to abandon AstraZeneca submitted cediranib (Recentin) as first-line treatment of colon cancer drug drug application. Earlier this year, the goods and Roche another blockbuster anticancer drug bevacizumab direct contrast to clinical studies also suffered defeat. Company spokesperson Abigail Baron said, "The results from two clinical studies, we feel in this area is no longer reason enough to go further." Entitled HORIZON Ⅱ clinical study compared the combination of chemotherapy and the product chemotherapy alone, the results show that the goods chemotherapy extended progression-free survival in patients with the disease, but patients overall survival compared to chemotherapy alone group did not improve. However, despite the first-line treatment in colon cancer failed, the goods in the treatment of other types of cancer, there are still some opportunities. An assessment of the product for the treatment of recurrent malignant glioma clinical study results will be announced in the near future, for lung cancer research is also underway.
AstraZeneca's cediranib Ⅲ clinical study fails again
ReplyDeleteIn the second pivotal clinical study suffered defeat after the results came out, the company decided to abandon AstraZeneca submitted cediranib (Recentin) as first-line treatment of colon cancer drug drug application. Earlier this year, the goods and Roche another blockbuster anticancer drug bevacizumab direct contrast to clinical studies also suffered defeat. Company spokesperson Abigail Baron said, "The results from two clinical studies, we feel in this area is no longer reason enough to go further." Entitled HORIZON Ⅱ clinical study compared the combination of chemotherapy and the product chemotherapy alone, the results show that the goods chemotherapy extended progression-free survival in patients with the disease, but patients overall survival compared to chemotherapy alone group did not improve. However, despite the first-line treatment in colon cancer failed, the goods in the treatment of other types of cancer, there are still some opportunities. An assessment of the product for the treatment of recurrent malignant glioma clinical study results will be announced in the near future, for lung cancer research is also underway.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
Tofacitinib
Fludarabine phosphate
Bardoxolone methyl
NSC 74859
Sorafenib Tosylate
SB-590885
Vemurafenib
Dabrafenib
GDC-0879
PLX-4720